Stock 603235 JIANGXI TIANXIN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials JiangXi Tianxin Pharmaceutical Co., Ltd.

Equities

603235

CNE100005Q89

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-10 pm EDT 		5-day change 1st Jan Change
26.37 CNY +3.33% Intraday chart for JiangXi Tianxin Pharmaceutical Co., Ltd. +4.93% +9.69%
12:00am Certain A Shares of JiangXi Tianxin Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 12-JUL-2024. CI
Apr. 29 JiangXi Tianxin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 12,748 10,524
Enterprise Value (EV) 1 10,456 8,325
P/E ratio 19.3 x 22.1 x
Yield 2.44% 2.08%
Capitalization / Revenue 5.53 x 5.59 x
EV / Revenue 4.54 x 4.42 x
EV / EBITDA 15 x 15.3 x
EV / FCF 59.4 x -297 x
FCF Yield 1.68% -0.34%
Price to Book 3.14 x 2.49 x
Nbr of stocks (in thousands) 437,780 437,780
Reference price 2 29.12 24.04
Announcement Date 4/21/23 4/23/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 2,025 2,304 2,522 2,305 1,882
EBITDA 1 890.3 1,137 969.4 695.6 544.4
EBIT 1 817.2 1,048 862.1 572.2 408.8
Operating Margin 40.36% 45.5% 34.18% 24.83% 21.72%
Earnings before Tax (EBT) 1 856.6 1,047 873.4 725.8 565.2
Net income 1 727.7 887.1 743.9 622.1 475.9
Net margin 35.94% 38.51% 29.49% 26.99% 25.28%
EPS 2 1.847 2.250 1.888 1.510 1.090
Free Cash Flow 1 331.3 659.5 -619.3 176.2 -28.07
FCF margin 16.36% 28.63% -24.55% 7.64% -1.49%
FCF Conversion (EBITDA) 37.22% 57.98% - 25.33% -
FCF Conversion (Net income) 45.53% 74.34% - 28.32% -
Dividend per Share - - - 0.7100 0.5000
Announcement Date 6/22/22 6/22/22 6/22/22 4/21/23 4/23/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 736 674 365 2,292 2,200
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 331 659 -619 176 -28.1
ROE (net income / shareholders' equity) 54% 71.6% 48.6% 20.9% 11.5%
ROA (Net income/ Total Assets) 18.8% 23.5% 18.4% 9.37% 5.23%
Assets 1 3,872 3,779 4,046 6,638 9,098
Book Value Per Share 2 3.350 2.930 4.840 9.270 9.670
Cash Flow per Share 2 2.680 2.590 1.820 4.730 5.270
Capex 1 237 303 216 260 536
Capex / Sales 11.73% 13.16% 8.54% 11.3% 28.46%
Announcement Date 6/22/22 6/22/22 6/22/22 4/21/23 4/23/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
JIANGXI TIANXIN PHARMACEUTICAL CO., LTD. Stock JiangXi Tianxin Pharmaceutical Co., Ltd.
+9.69% 1.53B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+60.25% 846B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.56% 628B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.49% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.30% 322B
ABBVIE INC. Stock AbbVie Inc.
+9.64% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.15% 240B
ROCHE HOLDING AG Stock Roche Holding AG
+3.11% 224B
NOVARTIS AG Stock Novartis AG
+16.98% 223B
AMGEN INC. Stock Amgen Inc.
+12.87% 173B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603235 Stock
  4. Financials JiangXi Tianxin Pharmaceutical Co., Ltd.